Skip to content

Trial Summary

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)



ACTRN/NCT /ethics:


Scientific title:

Randomised Phase III Controlled Trials of Regorafenib containing regimens versus standard care in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Sponsor / Cooperative group:

Bayer HealthCare Pharmaceuticals Inc

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream Advanced Gastro-Oesophageal Cancer
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2016-11-06
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting
HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Phone08 8222 6140
Principal InvestigatorDr Timothy Price
Recruitment StatusRecruiting